Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00975767 · ClinicalTrials.gov registry record · Phase 1
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Mirati Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 126
- Enrollment target
NCT00975767 is a Phase 1 study that was terminated before completion, run by Mirati Therapeutics. The registered enrollment target is 126 participants.
The verdict
NCT00975767, a Phase 1 study, was terminated before completion, sponsored by Mirati Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 126 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the safety profile of MGCD265 when administered in combination with the marketed anticancer drugs erlotinib and docetaxel.
Interventions
- DRUG MGCD265+erlotinib
- DRUG MGCD265+docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2009-08 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00975767
The ClinicalTrials.gov registry entry for NCT00975767 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MGCD265+erlotinib is the first listed.
NCT00975767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00975767 about?
NCT00975767 is a clinical study titled "A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer". The main purpose of this study is to assess the safety profile of MGCD265 when administered in combination with the marketed anticancer drugs erlotinib and docetaxel.
What is the current status of trial NCT00975767?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 126 participants. The study started on 2009-08. Estimated completion is 2014-08.
What interventions are being tested in trial NCT00975767?
The interventions under investigation include: MGCD265+erlotinib (DRUG), MGCD265+docetaxel (DRUG).
Who is sponsoring clinical trial NCT00975767?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.